Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
ConditionMild Cognitive Impairment (MCI)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age55-80
SponsorPravat Mandal
About this trial
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Eligibility criteria
Qualifiers
Memory complaints;
MCI diagnosis
MoCA score between 18-25
Age 55 - 80 years old.
Disqualifiers
Subjects with acute head trauma or head injury involving loss of consciousness;
Subjects with a history of cancer;
Subjects with a history of schizophrenia, manic-depressive disorder
Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
Trial design
Treatments tested in this trial
- Gamma- Glutamylcysteine
- Gamma- Glutamylcysteine
- Gamma- Glutamylcusteine
Treatment groups
9 Participants
are divided into 3 treatment groupsSponsors and collaborators
Pravat Mandal
Lead sponsor
University of Pittsburgh
Sponsor institution
Robert J. Coury Family - Mylan Foundation
Collaborator
Inid Research Lab
Collaborator
Source ClinicalTrials.gov